MTOR and gastric cancer: It was shown that isorhamnetin was able to inhibit MKN-45 autophagy in gastric cancer cells in a hypoxic environment by targeting PI3K and regulating the PI3K/Akt/mTOR signaling pathway, which inhibits gastric cancer cell proliferation and further development of gastric cancer; therefore isorhamnetin is a promising candidate for the treatment of gastric cancer [39].